Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 16Unknown 6Recruiting 6Withdrawn 2Terminated 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 11Myeloid 2Lymphoid 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Biphenotypic, Acute 1

Interventions

fludarabine 23Cyclophosphamide 23fludarabine phosphate 18Tacrolimus 16ruxolitinib 15Melphalan 15Azacitidine 14venetoclax 13Whole-Body Irradiation 12Mycophenolic Acid 12Cytarabine 11Busulfan 11Thiotepa 9Specimen Handling 9Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8Decitabine 8Biopsy 8Peripheral Blood Stem Cell Transplantation 7Imatinib Mesylate 7decitabine and cedazuridine drug combination 6Sirolimus 6Methotrexate 6thymoglobulin 5nilotinib 5X-Rays 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Magnetic Resonance Spectroscopy 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Idarubicin × Myeloid × Clear all
NCT06034470 2026-05-07

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT03164057 2026-04-23

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
206 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡